ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.47
-0.49%
US Tech 100
19,430.40
0.14%
S&P 500
5,487.03
0.25%
US Dollar vs CAD
1.3713
-0.03%
Bitcoin
64,926.72
-0.33%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) News

FATE

Fate Therapeutics (FATE)

Fate Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FATE
DateTimeSourceHeadlineSymbolCompany
06/11/20245:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
06/11/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
06/11/20243:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
06/11/20243:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
06/10/20244:05PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FATEFate Therapeutics Inc
06/10/20243:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
06/07/20244:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
06/04/20243:01PMGlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
05/31/20244:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
05/29/20243:01PMGlobeNewswire Inc.Fate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
05/09/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
05/09/20243:01PMGlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
05/09/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
05/09/20247:30AMGlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
05/06/20247:00AMGlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
05/03/20243:30PMGlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
04/22/20243:30PMGlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
04/03/20247:00AMGlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
04/02/20243:01PMGlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
03/19/20247:44AMGlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
03/05/20243:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
03/05/20243:01PMGlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
03/04/202412:29PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
03/01/20247:00AMGlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
02/26/20243:10PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
02/26/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
02/26/20243:01PMGlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
02/15/20247:00AMGlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
02/12/20245:06PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
02/02/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Your Recent History

USOTC
URNAF
Urbana (PK)
USOTC
SOHVY
Sumitomo Heavy Industries (PK)
USOTC
SAGXF
AB Sagax (PK)
ASX
MMZ
Mooter Media
BIT
P1SW20
BNP Paribas Issuance
BIT
UC4CTP
Unicredit Bank
COIN
ACEDBTC
EU
FRSG00014FS2
SG Issuer Sg Issuer Zc F...
USOTC
ROHCY
Rohm (PK)
ASX
LDX
Lumos Diagnostics
USOTC
IGRW
Interactive Health Network (CE)
EU
NL0015001OM3
Netherlands Domestic bon...
LSE
BP41
Barclays 27
COIN
BTCVLGBP
BIT
UB59MT
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved